Pfizer releases 2015 annual review

Pfizer today released its 2015 integrated annual review, which is an in-depth look at the company’s financial, social and environmental performance.

Pfizer marked last year as a breakthrough year for scientific research, collaborations and partnerships.

The review consisted of an in-depth look at Pfizer’s projects created to discover and develop new medicines and vaccines aimed at improving patient health conducted by scientists, researchers and business leaders.

During 2015, Pfizer saw significant scientific advancements across many of its therapeutics areas through its research and partnerships. The R&D department saw the advancement of 39 new potential therapies. This represents the biggest growth in Pfizer’s history.

The company’s oncology research brought about five immune-oncology assets in human studies that could possibly address the needs of cancer patients who require urgent therapy. Pfizer also saw the advancement of its investigational vaccines research that could combat deadly infectious diseases.

Pfizer made great efforts in 2015 to ensure that its medications were available on a worldwide scale. Last year saw a significant expansion for RxPathways, giving more than 250,000 people access to Pfizer medicines. The company also continued its partnership with the International Trachoma Initiative, at the Task Force for Global Health, to try to eliminate preventable blindness, among other partnerships.